Vertex Stock Plunges Over Pain Drug's Disappointing Study Results -- WSJ

Dow Jones12-20

By Joseph Walker

Shares of Vertex Pharmaceuticals sank Thursday, following disappointing study results for a non-opioid painkiller.

Vertex said the drug significantly reduced pain in people with a common form of lower back pain in a Phase 2 study. But patients who got a placebo saw similar improvements- raising concerns about the drug's future and if it will work in a new, larger study needed for approval.

It was a blow to hopes the drug, suzetrigine, could become a big seller.

"We believe the results overall raise major questions about whether the drug can ultimately succeed" in treating a form of back pain that represents about 40% of all chronic pain cases, said RBC Capital Markets analyst Brian Abrahams in a note to clients.

Shares in Vertex recently stood about 12% lower.

Vertex said the Phase 2 study wasn't designed to compare the patients who received its drug with those who received a placebo. Vertex said it will talk with the Food and Drug Administration about how to best design a Phase 3 study in lower back pain.

Vertex's suzetrigine is pending approval to treat acute pain, a different use than the subject of the newly released study, with a decision by the FDA expected by Jan. 30.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

December 19, 2024 11:01 ET (16:01 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492510849?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 00:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492510849","market":"sg","top_or_hot":-1,"title":"Vertex Stock Plunges Over Pain Drug's Disappointing Study Results -- WSJ","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Joseph Walker \n</p>\n<p>\n     Shares of Vertex Pharmaceuticals sank Thursday, following disappointing study results for a non-opioid painkiller. \n</p>\n<p>\n     Vertex said the drug significantly reduced pain in people with a common form of lower back pain in a Phase 2 study. But patients who got a placebo saw similar improvements- raising concerns about the drug's future and if it will work in a new, larger study needed for approval. \n</p>\n<p>\n     It was a blow to hopes the drug, suzetrigine, could become a big seller. \n</p>\n<p>\n     \"We believe the results overall raise major questions about whether the drug can ultimately succeed\" in treating a form of back pain that represents about 40% of all chronic pain cases, said RBC Capital Markets analyst Brian Abrahams in a note to clients. \n</p>\n<p>\n     Shares in Vertex recently stood about 12% lower. \n</p>\n<p>\n     Vertex said the Phase 2 study wasn't designed to compare the patients who received its drug with those who received a placebo. Vertex said it will talk with the Food and Drug Administration about how to best design a Phase 3 study in lower back pain. \n</p>\n<p>\n     Vertex's suzetrigine is pending approval to treat acute pain, a different use than the subject of the newly released study, with a decision by the FDA expected by Jan. 30. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 11:01 ET (16:01 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Stock Plunges Over Pain Drug's Disappointing Study Results -- WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Stock Plunges Over Pain Drug's Disappointing Study Results -- WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 00:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Joseph Walker \n\n\n     Shares of Vertex Pharmaceuticals sank Thursday, following disappointing study results for a non-opioid painkiller. \n\n\n     Vertex said the drug significantly reduced pain in ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2362541273.HKD","symbol_name":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492510849","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492510849","pubTimestamp":1734624060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Vertex Pharmaceuticals sank Thursday, following disappointing study results for a non-opioid painkiller.Vertex said the drug significantly reduced pain in people with a common form of lower back pain in a Phase 2 study. But patients who got a placebo saw similar improvements- raising concerns about the drug's future and if it will work in a new, larger study needed for approval.It was a blow to hopes the drug, suzetrigine, could become a big seller.\"We believe the results overall raise major questions about whether the drug can ultimately succeed\" in treating a form of back pain that represents about 40% of all chronic pain cases, said RBC Capital Markets analyst Brian Abrahams in a note to clients.Vertex said the Phase 2 study wasn't designed to compare the patients who received its drug with those who received a placebo. Vertex said it will talk with the Food and Drug Administration about how to best design a Phase 3 study in lower back pain.Vertex's suzetrigine is pending ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","VRTX":"福泰制药","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4532":"文艺复兴科技持仓","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4585":"ETF&股票定投概念","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","VTNR":"顶点能源","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4139":"生物科技","LU0079474960.USD":"联博美国增长基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0566484027.USD":"安本美国小盘成长股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","VERX":"Vertex, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4588":"碎股","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4138":"石油与天然气的炼制和营销","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"Vertex股价因止痛药令人失望的研究结果而暴跌——《华尔街日报》","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTNR":1,"VRTX":1,"VERX":1},"content_text":"By Joseph Walker \n\n\n     Shares of Vertex Pharmaceuticals sank Thursday, following disappointing study results for a non-opioid painkiller. \n\n\n     Vertex said the drug significantly reduced pain in people with a common form of lower back pain in a Phase 2 study. But patients who got a placebo saw similar improvements- raising concerns about the drug's future and if it will work in a new, larger study needed for approval. \n\n\n     It was a blow to hopes the drug, suzetrigine, could become a big seller. \n\n\n     \"We believe the results overall raise major questions about whether the drug can ultimately succeed\" in treating a form of back pain that represents about 40% of all chronic pain cases, said RBC Capital Markets analyst Brian Abrahams in a note to clients. \n\n\n     Shares in Vertex recently stood about 12% lower. \n\n\n     Vertex said the Phase 2 study wasn't designed to compare the patients who received its drug with those who received a placebo. Vertex said it will talk with the Food and Drug Administration about how to best design a Phase 3 study in lower back pain. \n\n\n     Vertex's suzetrigine is pending approval to treat acute pain, a different use than the subject of the newly released study, with a decision by the FDA expected by Jan. 30. \n\n\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 11:01 ET (16:01 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492510849"}